Literature DB >> 14697316

Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice.

Diana Zala1, Jean-Charles Bensadoun, Luis Pereira de Almeida, Blair R Leavitt, Claire-Anne Gutekunst, Patrick Aebischer, Michael R Hayden, Nicole Déglon.   

Abstract

Ciliary neurotrophic factor (CNTF) has been shown to prevent behavioral deficits and striatal degeneration in neurotoxic models of Huntington's disease (HD), but its effect in a genetic model has not been evaluated. Lentiviral vectors expressing the human CNTF or LacZ reporter gene were therefore injected in the striatum of wild-type (WT) and transgenic mice expressing full-length huntingtin with 72 CAG repeats (YAC72). Behavioral analysis showed increased locomotor activity in 5- to 6-month-old YAC72-LacZ mice compared to WT-LacZ animals. Interestingly, CNTF expression reduced the activity levels of YAC72 mice compared to control animals. In both WT and YAC72 mice, CNTF expression was demonstrated in striatal punches, up to a year after lentiviral injection. Stereological analysis revealed that the number of LacZ and DARPP-32-positive neurons were decreased in YAC72-LacZ mice compared to WT-LacZ animals. Assessment of the benefit of CNTF expression in the YAC72 mice was, however, complicated by a down-regulation of DARPP-32 and to a lesser extent of NeuN in all mice treated with CNTF. The expression of the neuronal marker NADPH-d was unaffected by CNTF, but expression of the astrocytic marker glial fibrillary acidic protein (GFAP) was increased. Finally, a reduction of the number of striatal dark cells was observed in YAC mice treated with CNTF compared to LacZ. These data indicate that sustained striatal expression of CNTF can be achieved with lentiviruses. Further studies are, however, needed to investigate the intracellular signaling pathways mediating the long-term effects of CNTF expression on dopamine signaling, glial cell activation and how these changes may affect HD pathology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14697316     DOI: 10.1016/j.expneurol.2003.09.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  23 in total

Review 1.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

2.  High-efficiency gene transfer into cultured embryonic motoneurons using recombinant lentiviruses.

Authors:  Florian L P Bender; Matthias Fischer; Natalja Funk; Nadiya Orel; Axel Rethwilm; Michael Sendtner
Journal:  Histochem Cell Biol       Date:  2006-11-11       Impact factor: 4.304

3.  Targeted knock-down of neuronal nitric oxide synthase expression in basal forebrain with RNA interference.

Authors:  Vasiliki Mahairaki; Leyan Xu; Mohamed H Farah; Glen Hatfield; Eddy Kizana; Eduardo Marbán; Vassilis E Koliatsos
Journal:  J Neurosci Methods       Date:  2009-02-28       Impact factor: 2.390

Review 4.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 5.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

6.  Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

Authors:  Yun-Feng Li; Yu-Fang Cheng; Ying Huang; Marco Conti; Steven P Wilson; James M O'Donnell; Han-Ting Zhang
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

Review 7.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

8.  Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.

Authors:  Jason Miller; Montserrat Arrasate; Benjamin A Shaby; Siddhartha Mitra; Eliezer Masliah; Steven Finkbeiner
Journal:  J Neurosci       Date:  2010-08-04       Impact factor: 6.167

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.

Authors:  Jose R Pineda; Raúl Pardo; Diana Zala; Hua Yu; Sandrine Humbert; Frédéric Saudou
Journal:  Mol Brain       Date:  2009-10-27       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.